Abstract
We studied the characteristics of [3H]cocaine binding to membranes prepared from whole guinea pig brain. Cocaine binding was specific and saturable. A one-site binding model fit the data adequately: the Kd value of [3H]cocaine was 44 nM with a Bmax value of 280 fmol/mg protein. The rank order of potency for the [3H]cocaine binding site was paroxetine > clomipramine > (−)-cocaine > fluoxetine > mazindol > desipramine > GBR12909 > phencyclidine > benztropine > GBR12935 > (+)-cocaine. The IC50 values of these drugs for inhibition of [3H]cocaine binding were highly correlated with their IC50 values for inhibition of [3H]5-HT uptake into synaptosomes prepared from whole guinea pig brain. High affinity 5-HT uptake inhibitors produced dose-dependent wash-resistant (pseudoirreversible) inhibition of [3H]cocaine binding. The wash-resistant inhibition produced by paroxetine was due to an increase in the Kd of [3H]cocaine binding sites, and was accompanied by an increase in the dissociation rate, consistent with an allosteric mechanism. These studies suggest that, using membranes prepared from whole guinea pig brain, [3H]cocaine labels a binding site associated with serotonin transporter and that paroxetine and cocaine bind to different sites on the serotonin transporter.
Similar content being viewed by others
Abbreviations
- GBR12909:
-
1-(2-{bis(4-fluorophenyl)methoxy}ethyl)-4-{3-phenylpropyl}piperazine
- TCP:
-
1-{1-(2-thienyl)cyclohexyl}piperidine
- BTCP:
-
N-{1-(2-benzo(b)thiophenyl)cyclohexyl}piperidine
- PCP:
-
1-(1-phenylcyclohexyl)piperidine
- GBR12935:
-
(1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine)
- CMI:
-
clomipramine
References
Van Dyke, C. 1981. Baltimore: Williams and Wilkins, Cocaine, in: Substance Abuse: Clinical Problems and Perspectives, pp. 158–166.
Post, R. M., and Contel, N. R. 1983. Human and animal studies of cocaine:implications for development of behavioral pathology. Pages 169–203,in Creese 1 (ed) Stimulants:neurochemical behavioral and clinical perspectives.
Pitts, D. K., and Marwah, J. 1987. Cocaine interaction with central monoaminergic neurotransmission. Pharmacol. Biochem. Behav. 26:453–461.
Gold, M. S., and Vereby, K. 1984. The Psychopharmacology of cocaine. Psychiatr. Ann. 14:714–723.
Ross, R. B., and Renyi, A. L. 1967. Inhibition of the uptake of tritiated catecholamines by anti-depressants and related compounds. Eur. J. Pharmacol. 2:181–186.
Koe, B. K. 1976. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp. Ther. 199:649.
Sershen, H., Reith, M. E. A., and Lajtha, A. 1980. The pharmacological relevance of the cocaine binding site in mouse brain. Neuropharmacol. 19:1145–1148.
Sershen, H., Reith, M. E., and Lajtha, A. 1982. Comparison of the properties of central and peripheral binding sites for cocaine. Neuropharmacology. 21:469–474.
Kennedy, L. T., and Hanbauer, I. 1983. Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J. Neurochem. 41:172–178.
Calligaro, D. O., and Eldefrawi, M. E. 1988. High affinity stereospecific binding of [3H]cocaine in striatum and its relationship to the dopamine transporter. Memb Biochem 7:87–106.
Ritz, M. C., Lamb, R. J., Goldberg, S. R., and Kuhar, M. J. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223.
Imperato, A., Puglisi-Allegra, S., Zocchi, A., Scrocco, M. G., Casolini, P., and Angelucci, L. 1990. Stress activation of limbic and cortical dopamine release is prevented by ICS 205-930 but not by diazepam. Eur. J. Pharmacol. 175:211–214.
Imperato, A., and Angelucci, L. 1989. 5-HT3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neurosci. Lett. 101:214–217.
Jiang, L. H., Ashby, C. R., Jr., Kasser, R. J., Wang, R. Y. 1990. The effect of intraventricular administration of the 5-HT3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric study. Brain Res. 513:156–160.
Ashby, C. R., Jr., Jiang, L. H., and Wang, R. Y. 1990. Chronic BRL 43694, a selective 5-HT3 receptor antagonist, fails to alter the number of spontaneiously active midbrain dopamine neurons. Eur. J. Pharmacol. 175:347–350.
Reith, M. E., Sershen, H., Allen, D. L., and Lajtha, A. 1983. A portion of [3H]cocaine binding in brain is associated with serotonergic neurons. Mol. Pharmacol. 23:600–606.
Rothman, R. B. 1986. Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies. Alcohol and Drug Res. 6:309–325.
Rothman, R. B., Long, J. B., Bykov, V., Jacobson, A. E., Rice, K. C., and Holaday, J. W. 1988. Beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J. Pharmacol. Exp. Ther. 247:405–416.
Lowry, O. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265–275.
Rodbard, D., Lenox, R. H., Wray, L., and Ramseth, D. 1976. Statistical characterization of the random errors in the radioimmunoassay dose-response variable. Clin. Chem. 22:350–358.
Rovati, G. E., Rodbard, D., and Munson, P. J. 1988. DESIGN: computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. I. Homologous and heterologous binding to one or two classes of sites. Anal. Biochem. 174:636–649.
McGonigle, P., Neve, K. A., and Molinoff, P. B. 1986. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Mol. Pharmacol. 30:329–337.
Knott, G. D., and Reece, D. K. 1972. MLAB: a civilized curve fitting system. Proceedings of the Online 1972 International Conference 1:497–526.
Rothman, R. B., Reid, A. A., Monn, J. A., Jacobson, A. E., and Rice, K. C. 1989. The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. Mol. Pharmacol. 36:887–896.
Van der Zee, P., Koger, H. S., Gootjes, J., and Hespe, W. 1980. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 15:363–370.
De Costa, B. R., George, C., and Dominguez, C. 1992. Approach to isothiocyanato-N-[1-(2-benzo(b)thiophenyl)cyclohexyl}piperidine, potential irreversible ligands at the dopamine transporter site. J. Chem. Soc. Perk. Trans. I. (In Press).
Marcusson, J. O., Bergstrom, M., Eriksson, K., and Ross, S. B. 1988. Characterization of [3H]paroxetine binding in rat brain. J. Neurochem. 50:1783–1790.
De Souza, E. B., and Kuyatt, B. L. 1987. Autoradiographic localization of3H-paroxetine-labeled serotonin uptake sites in rat brain. Synapse. 1:488–496.
Reith, M. E., Sershen, H., and Lajtha, A. 1981. Binding of [3H]cocaine in mouse brain: kinetics and saturability. J. Recept. Res. 2:233–243.
Reith, M. E. A., Sershen, H., and Lajtha, A. 1986. Binding site for [3H]cocaine in mouse striatum and cerebral cortex have different dissociation kinetics. J. Neurochem. 46:309–312.
Andersen, P. H. 1989. The dopamine uptake inhibitor GBR12909, selectivity and molecular mechanism of action. Eur. J. Pharmacol. 166:493–504.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akunne, H.C., de Costa, B.R., Jacobson, A.E. et al. [3H]cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: Allosteric modulation by paroxetine. Neurochem Res 17, 1275–1283 (1992). https://doi.org/10.1007/BF00968412
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00968412